

THE INTERNATIONAL SYMPOSIUM ON EBV & KSHV, RELATED AGENTS & DISEASES – 3RD JOINT MEETING

JUNE 29 – JULY 3, 2024

HILTON BOSTON PARK PLAZA
BOSTON, USA

FINAL PROGRAM

WWW.EBV.KSVIRUS.ORG

THANKS TO OUR SPONSORS!

Gold Sponsor:

National Cancer Institute, NIH Grant

Funding for this conference was made possible (in part) by 1R13CA294854-01 from the National Cancer Institute. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

Journal Sponsors:

pathogens
an Open Access Journal by MDPI

KSHV
EBV

BOSTON 2024

TABLE OF CONTENTS



Dear Colleagues,

We are excited to welcome you to Boston for the *International Symposium on EBV & KSHV & Related Agents and Diseases – 3rd Joint Meeting!* What an exciting year for this joint symposium, which will take place on the *60th and 30th anniversaries of the discoveries of EBV and KSHV, respectively*. This joint meeting will bring together researchers studying the oncogenic gamma-herpesviruses EBV and KSHV, as well as related agents, including murine gammaherpesvirus-68. Sessions will highlight viral pathogenesis, viral latency and reactivation, viral gene expression and replication, host responses to infection and autoimmunity, epidemiology, vaccine development, and therapeutic intervention.

The EBV / KSHV 2024 scientific advisory board (SAB) has formulated an innovative and thematic program for researchers interested in EBV and/or KSHV.

Our conference setting in Boston brings a vibrant fusion of history, culture, and summer festivities! With its blend of historical significance, cultural vibrancy, and summer festivities, Boston promises an unforgettable experience for conference attendees.

Sincerely,

EBV-KSHV Local Organizing Committee

- Benjamin E. Gewurz, Brigham & Women's Hospital and Harvard Medical School, USA (Co-Chair)
- Kenneth M. Kaye, Brigham and Women's Hospital and Harvard Medical School, Infectious Disease, USA (Co-Chair)
- Ann M. Moormann, UMass Chan Medical School, USA
- Mandy Muller, University of Massachusetts, USA
- Erle S. Robertson, Perelman School of Medicine, University of Pennsylvania, USA
- Bo Zhao, Brigham and Women's Hospital, Department Medicine, USA



EBV-KSHV Local Organizing Committee

- **Benjamin E. Gewurz**, Brigham & Women's Hospital and Harvard Medical School, USA (Co-Chair)
- **Kenneth M. Kaye,** Brigham and Women's Hospital and Harvard Medical School, Infectious Disease, USA (Co-Chair)
- **Ann M. Moormann,** UMass Chan Medical School, USA
- **Mandy Muller,** University of Massachusetts, USA
- **Erle S. Robertson,** Perelman School of Medicine, University of Pennsylvania, USA
- **Bo Zhao**, Brigham and Women's Hospital, Department Medicine, USA

Scientific Advisory Board

- **Richard F. Ambinder,** Johns Hopkins Medical School, USA
- **Eleni Anastasiadou**, Università di Roma La Sapienza, Italy
- **Alberto Ascherio**, Harvard TH Chan School of Public Heal, Harvard Medical School, USA
- **Sumita Bhaduri-McIntosh,** University of Florida, USA
- **Qiliang Cai,** Fudan University, School of Basic Medical Science, P.R.China
- **Ethel Cesarman**, Weill Cornell Medical College, USA
- **Mei-Ru Chen**, Taiwan University, (NTU)
- **Alan Kwok Shing Chiang**, University of Hong Kong, China
- **Jeffrey Cohen**, NNIH, NIAID/DIR, NIH,USA
- **Nicholas Conrad**, University of Texas Southwestern, USA
- **Jennifer Corcoran,** University of Calgary, Canada
- **Blossom Damania**, University of North Carolina Chapel Hill, USA
- **Henri-Jacques Delecluse**, German Cancer Research Center, Germany
- **Hongyu Deng**, Chinese Academy of Sciences, China
- **Alison Didychuk,** Yale University, USA
- **Dirk Dittmer**, University of North Carolina Chapel Hill, USA
- **Paul Farrell**, Imperial College, UK
- **Pinghui Feng**, University of South Carolina, USA
- **Erik Flemington**, Tulane University School of Medicine, USA
- **Craig Forrest**, University of Arkansas, USA
- **Lori Frappier**, University of Toronto, Canada
- **Marta Gaglia**, University of Wisconsin Madison, USA
- **Shou-Jiang (SJ) Gao**, University of Pittsburgh School of Medicine, USA
- **Britt Glaunsinger**, University of California Berkeley, USA
- **Eva Gottwein**, Northwestern University, USA
- **Henry Gruffat,** University of Lyon, France
- **Adam Grundhoff,** Leibniz Institute of Virology, Germany

- **Wolfgang Hammerschmidt**, Helmholtz Center, Germany
- **Meaghan Hancock**, Oregon Health and Science University, USA
- **Yasuaki Harabuchi**, Asahikawa Medical College, Japan
- **Young-Kwon Hong**, USC Keck School of Medicine, USA
- **Yoshihiro Izumiya**, University of California Davis, USA
- **Hem Chandra Jha,** Indian Institute of Technology Indore, India
- **Wei-Hua Jia**, Sun Yat-Sen Cancer Center, P.R. China
- **Dong-Yan Jin**, University of Hong Kong, Hong Kong
- **Eric Johannsen**, University of Wisconsin Madison, USA
- **Jae Jung**, Lerner Research Institute, Cleveland Clinic, USA
- **Teru Kanda**, Tohoku Medical and Pharmaceutical University, Japan
- **John Karijolich**, Vanderbilt University Medical Center, USA
- **Shannon Kenney,** University of Wisconsin Madison, USA
- **Rajiv Khanna**, Queensland Institute of Medical Research, Australia
- **Arnd Kieser**, Helmholtz Center Munich, Germany
- **Hiroshi Kimura**, Nagoya University, Japan
- **Leah Kottyan**, Cincinnati Children's Hospital, USA
- **Laurie Krug**, Center for Cancer Research, NCI, NIH, USA
- **Ke Lan,** Wuhan University, China
- **Michael Lagunoff,** University of Washington, USA
- **Lorenzo Leoncini**, University of Siena, Italy
- **Renfeng Li,** University of Pittsburgh, USA
- **Paul Lieberman**, The Wistar Institute, USA
- **Kwok Wai Lo**, The Chinese University of Hong Kong, China
- **Richard Longnecker**, Northwestern University Medical School, USA
- **Micah Luftig,** Duke Medical School, USA
- **Mark Manzano**, University of Arkansas for Medical Sciences, USA
- **Jeff Martin**, University of California San Francisco, USA
- **Olivia Martinez**, Stanford University School of Medicine, USA
- **George Miller,** Yale University, USA
- **Ashlee Moses**, Oregon Health Sciences University, USA
- **Christian Munz**, University of Zurich, Switzerland
- **Takayuki Murata**, Fujita Health University, Japan
- **Paul Murray**, University of Limerick, Ireland
- **Javier Gordon Ogembo**, City of Hope, USA
- **Sidney Ogolla**, Kenya Medical Research Institute, Kenya
- **Päivi Ojala**, University of Helsinki, Finland
- **Nancy Raab-Traub**, University of North Carolina, USA
- **Ramya Ramaswami**, NCI, National Institutes of Health, USA
- **Rolf Renne**, University of Florida, USA

- **Rosemary Rochford**, University of Colorado Anschutz School of Medicine, USA
- **Cyprian Rosetto**, University of Nevada Reno, USA
- **Abhik Saha**, Presidency University, India
- **Clare Sample**, Penn State Medical Center, USA
- **Jeffery Sample**, Penn State College of Medicine, USA
- **Thomas Schulz,** Institute of Virology, Hannover Medical School, Germany
- **Rona Scott,** Louisiana State University, USA
- **Claire Shannon-Lowe**, University of Birmingham, UK
- **Neelam Sharma-Walia**, Rosalind Franklin University, USA
- **Rebecca Skalsky,** Oregon Health & Science University, USA
- **Bill Sugden**, University of Wisconsin Madison, USA
- **Sankar Swaminathan**, University of Utah, USA
- **Vera Tarakanova**, Medical College of Wisconsin, USA
- **Graham Taylor**, University of Birmingham, UK
- **Italo Tempera**, Wistar Institute, USA
- **Zsolt Toth,** University of Florida, USA
- **Jennifer Totonchy**, Chapman University, USA
- **Jessica M. Tucker**, University of Iowa Carver College of Medicine, USA
- **Linda van Dyk,** University of Colorado Anschutz School of Medicine, USA
- **Subhash Verma**, University of Nevada, USA
- **Matt Weirauch,** Cincinnati Children's Hospital, USA
- **Michelle West**, University of Sussex, UK
- **Denise Whitby**, Frederick National Laboratory for Cancer Research, USA
- **Rob White**, Imperial College London, UK
- **Charles Wood**, LSU Health Sciences Center, USA
- **Ting-Ting Wu**, University of California Los Angeles, USA
- **Miao Xu**, Sun Yat-sen University Cancer Center, China
- **Robert Yarchoan**, National Cancer Institute, USA
- **Lawrence S. Young**, University of Warwick, UK
- **Yan Yuan**, University of Pennsylvania, USA
- **Musheng Zeng**, Sun Yat-Sen University, China
- **Zhi-Ming Zheng**, Center for Cancer Research, NCI, NIH, USA
- **Fanxiu Zhu**, Florida State University, ,USA
- **Joseph Ziegelbauer**, HIV and AIDS Malignancy Branch, NCI, USA

Meeting Manager

Joan Oefner, Rhema Association Management www.societymanagement.com

Session Moderators

- **Eleni Anastasiadou**, Sapienza university of Rome, Italy
- **Paola Chabay**, Instituto Multidisciplinario de Investigaciones en Patologías Pediátricas (IMIPP). CONICET-GCBA, Argentina
- **Jennifer Corcoran**, University of Calgary, Canada
- **Xinghong Dai**, Case Western Reserve University, United States
- **Allison Didychuk**, Yale University, United States
- **Marta Gaglia**, University of Wisconsin Madison, United States
- **Benjamin Gewurz**, Brigham & Women's Hospital and Harvard Medical School, United States
- **Eva Gottwein**, Northwestern University, United States
- **Rui Guo**, Tufts University, United States
- **Sizun Jiang**, BIDMC/Harvard Medical School, United States
- **John Karijolich**, Vanderbilt University Medical Center, United States
- **Kenneth Kaye**, Brigham and Women's Hospital, Harvard Medical School, United States
- **Arnd Kieser**, Helmholtz Center Munich - German Research Center for Environmental Health, Germany
- **Leah Kottyan**, Cincinnati Children's, United States
- **Laurie Krug**, National Cancer Institute, United States
- **Renfeng Li**, University of Pittsburgh, United States
- **Zhen Lin**, Tulane University Health Sciences Center, United States
- **Zhe Ma**, University of Florida, United States
- **Mark Manzano**, University of Arkansas for Medical Sciences, United States
- **Andrew McGuire**, Fred Hutch Cancer Center, United States
- **Michael McIntosh**, University of Florida, Pediatrics, United States
- **JJ Miranda**, Barnard College, Columbia University, United States
- **Ann Moormann**, Univ of Massachusetts Chan Med Sch, United States
- **Mandy Muller**, UMass Amherst, United States
- **Shunbin Ning**, East Tennessee State University, United States
- **Javier Ogembo**, Beckman Research Institute of City of Hope, United States
- **Sidney Ogolla**, Kenya Medical Research Institute, Kenya
- **Bernadett Papp**, University of Florida, United States
- **Alexander Price**, The Wistar Institute, Philadelphia, USA
- **Zhiqiang Qin**, University of Arkansas for Medical Sciences, United States
- **Ramya Ramaswami**, HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, United States
- **Erle Robertson**, Perelman School of Medicine, University of Pennsylvania, USA
- **Arunava Roy**, University of South Florida, United States
- **Yoshitaka Sato**, Nagoya University Graduate School of Medicine, Japan

- **Kathy Shair**, University of Pittsburgh, United States
- **Meir Shamay**, Azrieli Faculty of Medicine, Bar-Ilan University, Israel
- **Claire Shannon-Lowe**, The University of Birmingham, United Kingdom
- **Neelam Sharma-Walia**, Rosalind Franklin University of Medicine and Science, United States
- **Rebecca Skalsky**, VGTI, United States
- **Italo Tempera**, The Wistar Institute, United States
- **Zsolt Toth**, University of Florida, United States
- **Jennifer Totonchy**, Chapman University, United States
- **Jessica Tucker**, University of Iowa, United States
- **Nate Ungerleider**, Tulane University School of Medicine, United States
- **Chong Wang**, University of Minnesota, United States
- **Matthew Weirauch**, Cincinnati Children's Hospital, United States
- **Michelle West**, University of Sussex, United Kingdom
- **Rob White**, Imperial College London, United Kingdom
- **Christopher Whitehurst**, New York Medical College, United States
- **Miao Xu**, Sun Yat-sen University Cancer Center, China
- **Jun Zhao**, Cleveland Clinic Florida Research and Innovation Center, United States
- **Jian Zhu**, Ohio State University, United States



Student Abstract Awards

- **María Eugenia Amarillo**, (IMIPP), Argentina
- **Michelle Böni**, Switzerland
- **Beniah Brumbaugh**,United States
- **Guo-Long Bu**, Sun Yat-Sen University Cancer Center, China
- **Danielle Burner**, Duke University, United States
- **Jonathan Calero-Land**a, City of Hope, United States
- **Ashley Campbell**, University of Toronto, Canada
- **Alejandro Casco,** University of Wisconsin-Madison, United States
- **Catarina Costa**, Católica Biomedical Research Centre, Portugal
- **Nicholas Doak**, Yale University, United States
- **Sheila Gonzalez,** University of Iowa, United States
- **Mariel Kleer,** University of Calgary, Canada
- **Emmily Koech**, Kenya Medical Research Institute, Kenya
- **Rachael Kostelecky**, University of Colorado, United States
- **Ciara Leahy**, University of Limerick, Ireland
- **Davide Maestri**, The Wistar Institute, United States
- **Christian McDonald**, University of Miami, United States
- **Mahina Tabassum Mitul**, University of California Irvine, United States
- **Steven Mrurdock Jr,** University of Arkansas for Medical Sciences, United States
- **Uwesu Muki**, Muhimbili University of Hhealth and Allied Sciences, United Republic of Tanzania
- **Nilabja Roy Chowdhury**, Bar-Ilan University, Israel
- **Febri Sugiokto**, University of Pittsburgh, United States
- **Iyabode Tiamiyu**, Fred Hutch Cancer Center, United States
- **Krista Tuohinto**, University of Helsinki, RPU, CAN-PRO, Finland
- **Beatriz Veronese**, University of Florida, United States
- **Alexa Wilson,** Dalhousie University, Canada
- **Zhenyu Wu,** Ohio State univeristy, United States
- **Jia Xie**, University of Hong Kong, Hong Kong
- **Wajd Zakir,** Chapman University, United States
- **Travis Zeigler**, United States
- **Zhaoqin Zhang**, University of Birmingham, United Kingdom
- **Ling Zhong**, Sun Yat-sen university, China

CONGRATULATIONS TO ALL THE STUDENT ABSTRACT AWARD WINNERS!

Meeting Policy, Safety Plan

The organizers of the 2024 Joint Epstein-Barr Virus/Kaposi's Sarcoma Associated Herpesvirus Symposia is committed to provide a safe environment for all attendees. The venue is the Hilton Park Plaza Hotel in Boston, which is accessible to those with disabilities and has up to date compliance with safety codes and accessibility for all attendees.

We encourage transparent intellectual debate in a welcoming and inclusive, and safe environment and atmosphere. Organizers and session chairs will foster rigorous but courteous exchanges of all science presented in the oral and poster presentations, in a manner that is respectful to all conferees. The conference is focused on scientific exchange, and is not a platform for political expression. The conference will not tolerate unprofessional behavior including harassment of any kind. Specifically, no sexual, racial, ethnic, or religious harassment or discrimination will be tolerated.

To report any violation of the conference code of conduct, attendees will report violations to any of the local organizing committee members (Drs. Gewurz, Kaye, Moormann, Muller, Robertson, Zhao) who will all be present at the meeting, and the allegation will be kept confidential to the extent possible. Following report of a violation, Drs. Gewurz, Kaye, Moormann, Muller, Robertson and Zhao will meet to discuss the allegation and any evidence and make a decision as to whether the code of conduct has been violated. Those found in violation will be confidentially informed of the violation. Depending on the level of conduct violation, those in violation will either be given a one-time warning, or will be asked to depart the meeting.

Any attendee who has questions or concerns can approach any of the local organizers, Drs. Gewurz, Kaye, Moormann, Muller, Robertson or Zhao, who will respond to the question or concern and also report it to the other organizers. Reports of any violations will be recorded in written form by the conference organizers, along with a record of the resulting action for enforcement of conference policy.

Although not anticipated, for those with a Civil Rights concern, reports to the Department of Health and Human Services (HHS) Office of Civil Rights (OCR) will be available and the website https://www.hhs.gov/civil-rights/filing-a-complaint/index.html will be posted with the conference policy. Filing a complaint of discrimination with the conference organizers is not required prior to filing a discrimination complaint with HHS OCR. Further, seeking any assistance from the conference organizers in no way prohibits filing complaints with HHS OCR.

Please see https://grants.nih.gov/grants/policy/harassment/find-help.htm for more information. Individuals with questions, concerns or complaints related to any of the civil rights laws are encouraged to contact the HHS Office for Civil Rights, https://www.hhs.gov/ocr/about-us/contact-us/index.html

Information regarding how individuals can notify the NIH about any concerns of harassment, discrimination or other inappropriate conduct can be found at https://www.hhs.gov/ocr/complaints/index.html

Complaints must be filed within 180 days of when you knew that the act or omission complained of occurred. OCR may extend the 180-day period if you can show "good cause". To file a Civil Rights Complaint online, open the OCR Complaint Portal and select the type of complaint you would like to file.
For any serious adverse behavior that is beyond the ability of the conference organizers to handle, the organizers will work with appropriate personnel at the hotel venue, or otherwise contact the appropriate local authorities.
In the event of a medical emergency, medical personnel will be immediately called. The local emergency number is 911 from anywhere in the continental USA. This can be called from any cell phone or land line within the USA. The hotel venue is located very close to the Massachusetts General Hospital, which is a major tertiary care medical center. In the event of a disaster, the organizers will confer with appropriate local authorities as to the recommended actions.

EBV-KSHV Local Organizing Committee:

BENJAMIN E. GEWURZ, MD, PHD, (CO-CHAIR)

KENNETH M. KAYE, MD (CO-CHAIR)

ANN M. MOORMANN, PHD, MPH

MANDY MULLER, PHD

ERLE S. ROBERTSON, PHD



BO ZHAO, PHD

General Information

Abstracts

Please use the Oxford Abstracts online program to search and view abstracts. All meeting participants are encouraged to include a profile image and opt-in to the networking features to chat or message participants. Any changes to the program or abstracts made after the June 17th print deadline will be reflected in the online program.

ePoster Gallery

Please view the online ePoster gallery with pdf versions of the posters of participating authors. There's still time for poster authors to upload a one-page pdf of their posters, which is tied to the online program. Presenters can also include a video presentation and invite meeting participants to visit both the ePosters & in-person poster presentation, share on Twitter **#ebvkshv** and LinkedIn.

In-Person Posters

The poster boards will be set up in the Statler Room by 10:00 AM on Sunday, June 30th. Materials for fixing the posters to the boards will be available. Poster Session 1 presenters should set up their posters after 10 AM on Sunday and remove their posters from the boards immediately after the session ends. Poster Session 2 presenters can set up their posters from 7:30 AM on Monday and should remove their posters from the boards immediately after the session. The boards will be removed on Tuesday morning and must be empty. Poster Presenters should be at their posters during their scheduled poster session, ODD number posters the 1st hour, EVEN number posters the 2nd hour.

Oral Presentations

- All speakers should visit the speaker ready room (Commonwealth Room) at least an hour before scheduled session start time, to view their presentation and make any corrections before uploading from a thumb drive through the network to the appropriate session, with the assistance of the Speaker Ready Room AV Tech. All presentations will be deleted following the session.
- Alternatively, presenters can connect their thumb drive directly into the presentation laptop in their session room, and download presentation during the break before the session, or at least one hour prior to session start time (with the assistance of the AV technician in the room).
- Due to the high number of presentations and potential queue, it is highly recommended to preload presentations in the Commonwealth Room, an AV technician will be available 7 hours a day to assist speakers.

Presentations should be labeled as follows, Program ID_Last name
e.g., **Plenary 2.1_Yeo; Parallel 9.2_Burton; Keynote 2.1_Raab-Traub**

If any presentations include videos with audio, it is HIGHLY recommended to test in speaker ready room at least one hour before the start of the session & inform the AV technician if your presentation includes video with audio.

WiFi Access: Network Name: **ebvkshv** Password: **ebvkshv2024**

Location of Meeting Events

- Opening Session: Terrace Room on Lobby Level Saturday night Only
- Welcome Reception Saturday evening: Statler Room Mezzanine Level
- Plenary Sessions: Grand Ballroom A Mezzanine Level
- Parallel Sessions: Grand Ballroom A and Georgian Room, Mezzanine Level
- Poster Sessions: Statler Room, across from Grand Ballroom
- Coffee Breaks: Grand Ballroom B and Foyer
- Sunday Lunch – Panera Bread and Boston Public Garden
- Monday Lunch – Maggiano's Little Italy (next door to hotel)
- KSHV 2025 Organization Lunch Monday for those who replied, MJ O'Connor's at the Hilton
- Tuesday Lunch – Empire Garden in Chinatown
- Tuesday Gala Dinner – For those who registered, Avenue 34 at the Hilton

Continental Breakfast will be Available Every Morning from 7:15 – 8:00 am

There will be a Continental Breakfast (see online program for more details) each morning before the start of the Plenary Sessions. Please be sure to get to the Grand Ballroom area early so you can enjoy a leisurely breakfast or at least grab coffee, protein, fresh fruit and carbs to bring into the meeting room with you before the session begins. There will be coffee, tea and decaf at the mid-morning coffee breaks and coffee and soft-drinks at the afternoon breaks.

Lunches - Lunches have been organized on all three full days of the meeting, outside the hotel (hotel lunches would cost 2/3 more and we hope attendees will enjoy getting out a bit during the lunch breaks).

Welcome Reception & Poster Session Receptions

The food at the Welcome Reception on Saturday evening can be in lieu of dinner (especially for our student participants), and there will be a buffet at Sunday evening's Poster Session, but Monday's Poster Session is meant to be an after-dinner event.

SATURDAY, JUNE 29, 2024

Onsite Registration & Badge Pickup
3:30 - 7:15pm Saturday, 29th June
Room Terrace Room Foyer
Please stop by the registration desk to pick-up your meeting badge. We will also be able to take last minute onsite registrations.

Welcome & Introductions
5:00 - 5:15pm Saturday, 29th June
Room Terrace Room
Moderators Benjamin Gewurz, Kenneth Kaye

Plenary Session 1 Coinfection
5:15 - 7:15pm Saturday, 29th June
Terrace Room
Moderators Paola Chabay, Zsolt Toth

17:15 - 17:30 **Plenary 1.1 Epstein Barr Virus Synergizes with Plasmodium falciparum Malaria to Induce Aberrant Expression of Activation-Induced Cytidine Deaminase: Implications for Burkitt's lymphoma**, Bonface Ariera

17:30 - 17:45 **Plenary 1.2 The Protective Effect of Gammaherpesvirus on the Malaria lethality in Mouse Model.**, Viriato M'Bana

17:45 - 18:00 **Plenary 1.3 Repurposed Nitroxoline Inhibits Models of EBV- and KSHV-Associated Malignancies without HIV Reactivation**, JJ Miranda

18:00 - 18:15 **Plenary 1.4 High-resolution Antibody Profiling of KSHV-infected Individuals Presenting with and without Kaposi Sarcoma Reveals Distinct Viral-Exposure Signatures**, Dicle Yalcin

18:15 - 18:30 **Plenary 1.5 Role of HERV-K Np9 protein in KSHV-associated malignancies**, Zhiqiang Qin

18:30 - 18:45 **Plenary 1.6 A Persistent CD8+ HIV-Specific T-Cell Response in KS Tumors from Adults with HIV Despite Anti-Retroviral Therapy**, Iyabode Tiamiyu

18:45 - 19:00 **Plenary 1.7 Revealing the complexity of EBV type 1 and type 2 infection kinetics in a longitudinal study of Kenyan children**, Sin Ting Hui

19:00 - 19:15 **Plenary 1.8 KSHV Cooperates with EBV to Transform B Cells and Drive Lymphomagenesis**, Mitch Hayes

Welcome Reception
7:15-8:45pm Saturday, 29 June
Statler Room on the Mezzannine Level
Join us for the Welcome Reception, please pickup your badge first at the Terrace Room Registration Desk before 7:15 PM

SUNDAY, JUNE 30, 2024

Continental Breakfast & Registration
7:15 - 8:00am Sunday, 30th June
Grand Ballroom B & Ballroom Foyer

Plenary Session 2 Tumor Microenvironment
8:00 - 10:00am Sunday, 30th June
Grand Ballroom A
Moderators Eleni Anastasiadou, Eva Gottwein

08:00 - 08:15 **Plenary 2.1 Epstein-Barr Virus Orchestrates Spatial Reorganization and Immunomodulation Within the Classic Hodgkin Lymphoma Tumor Microenvironment**, Yao Yu Yeo

08:15 - 08:30 **Plenary 2.2 Spatial Characterisation of Immune Checkpoint Expressing CD8+ T-cell Subsets in Nasopharyngeal Carcinoma**, Graham Taylor

08:30 - 08:45 **Plenary 2.3 Multi-omic spatial profiling of the tumour microenvironment reveals correlates of malignant behavior in EBV-positive Hogkinoid lymphoproliferations**, Matthew Pugh

08:45 - 09:00 **Plenary 2.4 Spatially-Informed Prediction of HIV-Associated Non-Hodgkin Lymphoma Vulnerabilities by EBV Infection and Cell of Origin**, Elliott SoRelle

09:00 - 09:15 **Plenary 2.5 Expression Cloning Discovery of KSHV Epitopes Recognized by KS CD8+ Tumor Infiltrating Lymphocytes**, Iyabode Tiamiyu

09:15 - 09:30 **Plenary 2.6 High Dimensional, Single Cell Analysis of EBV-Specific T Cells from Pediatric Transplant Recipients with Elevated EBV DNAemia or Controlled Infection**, Edward Vizcarra

09:30 - 09:45 **Plenary 2.7 Burkitt Lymphoma: The DARKest Lymphoma Microenvironment**, Maria Chiara Siciliano

09:45 - 10:00 **Plenary 2.8 An Immunosuppressive Tumour Microenvironment, and not a Loss of Systemic Immunity to EBV Latent Antigens, Underpins the Pathogenesis of EBV-Positive Diffuse Large B-Cell Lymphoma**, Éanna Fennell

Coffee Break
10:00 - 10:30am Sunday, 30th June
Grand Ballroom B & Ballroom Foyer

Keynote Address I: Addressing latent viral infection in KS and lymphoma
Ethel Cesarman, Weill Cornell, USA
10:30 - 11:00am Sunday, 30th June
Grand Ballroom A - Moderator Kenneth Kaye

Parallel Session 3 Epigenetics, Gene Expression and Reactivation I
11:00am - 1:00pm Sunday, 30th June
Grand Ballroom A
Moderators John Karijolich, Renfeng Li

11:00 - 11:15 **Parallel 3.1 Regulation of KSHV latent chromatin by host inflammatory signaling via transcription memory**, Yoshihiro Izumiya

11:15 - 11:30 **Parallel 3.2 Natural Sequence Variation in Essential Epstein-Barr Virus Replication Factor EBNA1 Preserves Key Interfaces and Can Enhance Sensitivity to Inhibitors**, Michelle West

11:30 - 11:45 **Parallel 3.3 High-density Resolution of the KSHV Transcriptome Identifies Novel Transcript Isoforms Generated by Long-range Transcription and Alternative Splicing**, Ritu Shekhar

11:45 - 12:00 **Parallel 3.4 Regulation of EBV latent episomes by histone variant H2A.Z**, Leonardo Castro-Muñoz

12:00 - 12:15 **Parallel 3.5 A Short Linear Motif in KSHV ORF45 is Crucial for its Interaction with Members of the Host FOXK Transcription Factor Subfamily, which are Essential for the KSHV Lytic Cycle**, Bernadett Papp

12:15 - 12:30 **Parallel 3.6 Viral vIRF3 Cooperates with Cellular IRF4 to Drive IRF4 Super-Enhancer Activity through a Complex DNA Element**, Ziyan Liang

12:30 - 12:45 **Parallel 3.7 From Enhancers to Genome Conformation: Complex Transcriptional Control of a Single Herpesviral Gene**, David Morgens

12:45 - 13:00 **Parallel 3.8 Transcriptome Analysis of Burkitt Lymphoma cells treated with Anti-convulsant drugs that are Inhibitors of Epstein–Barr Virus Lytic Reactivation**, Kelly Gorre

Parallel Session 4 Innate and Adaptive Immunity I: Viral Evasion
11:00am - 1:00pm Sunday, 30th June
Georgian Room
Moderators Arunava Roy, Claire Shannon-Lowe, Shunbin Ning

11:00 - 11:15 **Parallel 4.1 KSHV MicroRNA-Mediated Repression of STING**, Kimberly Paulsen

11:15 - 11:30 **Parallel 4.2 Phenotype and tissue distribution of EBV specific immune control**, Christian Münz

11:30 - 11:45 **Parallel 4.3 The combination of proviral and antiviral roles of B cell-intrinsic STAT1 expression defines parameters of chronic gammaherpesvirus infection**, Vera Tarakanova

11:45 - 12:00 **Parallel 4.4 Kaposi Sarcoma-Associated Herpesvirus Induces Protective T Cell Responses in a Pre-Clinical in vivoModel**, Michelle Böni

12:00 - 12:15 **Parallel 4.5 Diminished Defenders: CD56neg NK cells limited impact on rituximab-mediated antibody dependent cell cytotoxicity against Burkitt lymphoma**, Catherine Forconi

12:15 - 12:30 **Parallel 4.6 Application of Epstein Barr Virus Proteome Microarrays to Characterize Humoral Immune Responses and Define Immune Signatures for Risk of EBV-Associated Cancers**, Denise L. Doolan

12:30 - 12:45 **Parallel 4.7 Potential Shift in Immunological Frontlines: Deviation of Cellular Recognition Strategies by NK and Gamma Delta T Cells in Endemic Burkitt Lymphoma**, Zachary Racenet

12:45 - 13:00 **Parallel 4.8 Homozygous ZAP70 mutations in a patient with EBV B cell lymphoproliferative disease**, Jeffrey Cohen

Lunch Break - Panera Bread 115 Stuart Street (at Tremont)
1:00 - 2:45pm Sunday, 30th June

During Sunday's lunch break take a 6 minute walk to Panera Bread to pickup a box lunch

Across from the Panera bread is Boston's famous Public Garden and Boston Common parks where we hope the weather will cooperate and attendees can enjoy al fresco dining.

The Boston Public Garden and Boston Commons is just a few blocks from the Panera Bread where we hope attendees can enjoy their sandwiches and some fresh air and networking. If anyone needs meeting staff to pick-up their lunches and bring them back to the hotel, please just ask at the registration desk.



EBV Association Board Meeting/Lunch
1:00 – 2:45pm Sunday, 30th June
Hancock Room

Parallel Session 5 Epigenetics, Gene Expression and Reactivation II
2:45 - 4:45pm Sunday, 30th June
Grand Ballroom A
Moderators Yoshitaka Sato, JJ Miranda

14:45 - 15:00 **Parallel 5.1 The EBV B-cell Lytic Switch**, Zhixuan Li

15:00 - 15:15 **Parallel 5.2 EBV reprograms chromatin loop extrusion to support cell proliferation**, Italo Tempera

15:15 - 15:30 **Parallel 5.3 KSHV genome harbors both constitutive and lytically induced enhancers**, Nilabja Roy Chowdhury

15:30 - 15:45 **Parallel 5.4 Functional Characterization of Epstein-Barr Virus encoded lnc-BARTs in Associated Tumors**, Honglin Chen

15:45 - 16:00 **Parallel 5.5 Kaposi's sarcoma herpesvirus latency-associated nuclear antigen is a bimodal regulator of viral gene expression and essential for lytic infection**, Nicholas Van Sciver

16:00 - 16:15 **Parallel 5.6 KSHV Genome Becomes Refractory to the Binding and Lytic Cycle Driving Activity of HIF-1α during De Novo KSHV Infection**, Zsolt Toth

16:15 - 16:30 **Parallel 5.7 Gammaherpesvirus Induced Retrotransposon Activation Drives mRNA Isoform Switching**, Azra Lari

16:30 - 16:45 **Parallel 5.8 Hypoxic Reactivation of Kaposi's Sarcoma Associated Herpesvirus: The art of Manipulating Host Machinery by KSHV**, Rajnish Singh

Parallel Session 6 Lytic Cycle/Viral Replication/Reactivation I
2:45 - 4:45pm Sunday, 30th June
Georgian Room
Moderators Rebecca Skalsky, Zhe Ma, Bernadett Papp

14:45 - 15:00 **Parallel 6.1 Remodeling of the ribosomal quality control and integrated stress response by viral ubiquitin deconjugases**, Jiangnan Liu

15:00 - 15:15 **Parallel 6.2 Targeting the OTUD4-USP7 Deubiquitinase Complex to Curb KSHV Lytic Reactivation**, Junjie Zhang

15:15 - 15:30 **Parallel 6.3 EBV BGLF4 Kinase is Packaged into the Extracellular Vesicles and Regulates the Constituents inside to Facilitate Virus Infection**, Mei-Ru Chen

15:30 - 15:45 **Parallel 6.4 The KSHV E3 Ubiquitin Ligase K3 Regulates the Unfolded Protein Response**, Alexa Wilson

15:45 - 16:00 **Parallel 6.5 Gene Expression Profiling and Genomic Analysis of Synthetic Lethal Sensitive and Resistant Cell Lines Derived from EBV+ and EBV- Diffuse Large B-cell Lymphomas**, Michael McIntosh

16:00 - 16:15 **Parallel 6.6 IFI16 recruits HDAC1 and 2 to deacetylate the KSHV Latency-Associated Nuclear Antigen (LANA), promoting latency**, Arunava Roy

16:15 - 16:30 **Parallel 6.7 Aquaporin 3 (AQP3) regulates oxidative stress and the life cycle of Kaposi sarcoma Herpesvirus (KSHV) in its associated cancers**, Neelam Sharma-Walia

16:30 - 16:45 **Parallel 6.8 DDX5 and DDX17 Facilitate Lytic Reactivation of Gammaherpesviruses**, Praneet Kaur Sandhu

Coffee Break
4:45 - 5:00pm Sunday, 30th June
Grand Ballroom B & Ballroom Foyer

Keynote Address II Elliott Kieff Memorial Lecture: Elliott Kieff and The Foundations of EBV Molecular Biology
Nancy Raab-Traub, UNC-Chapel Hill, USA
5:00 - 5:30pm Sunday, 30th June
Grand Ballroom A - Moderator: Erle Robertson



In Memoriam
5:30 - 5:45pm Sunday, 30th June
Grand Ballroom A

GEORGE SAI WAH TSAO, PhD
(10/28/1955 - 12/08/2022)

Poster Session 1
5:45 - 7:45pm Sunday, 30th June
Statler Room

Presenters will be at their posters as follows: Visit the ODD number Posters from 5:45 - 6:45 PM and the EVEN number Posters from 6:45 - 7:45 PM.
Food & Beverage and Bars will be setup in Grand Ballroom B and the Ballroom Foyer

MONDAY, JULY 1, 2024

Continental Breakfast
7:15 - 8:00am Monday, 1st July
Grand Ballroom B & Ballroom Foyer

Plenary Session 7 Transformation/oncogenesis I
8:00 - 10:00am Monday, 1st July
Grand Ballroom A
Moderators Mark Manzano, Arnd Kieser

08:00 - 08:15 **Plenary 7.1 The complete Kaposi Sarcoma-associated herpesvirus genome induces early-onset, metastatic angiosarcoma in transgenic mice**, Dirk Dittmer

08:15 - 08:30 **Plenary 7.2 Latent membrane protein 2A (LMP2A) determines dependence on antigen-induced signaling in Epstein-Barr virus (EBV) transformed lymphoblastoid cells**, Makoto Ohashi

08:30 - 08:45 **Plenary 7.3 Matched molecular clones of KSHV and EBV for functional analysis of viral cooperation**, Jan Knickmann

08:45 - 09:00 **Plenary 7.4 Single Cell Analysis of KSHV-induced Loss of Contact Inhibition in a Lymphatic Endothelial Cell Model of Kaposi's Sarcoma**, Eva Gottwein

09:00 - 09:15 **Plenary 7.5 Suppression of IRF6 Expression Promotes the Development of EBV+ Nasopharyngeal Carcinoma (NPC) by Inhibiting Epithelial Cell Differentiation and Preventing EBV Lytic Reactivation**, Shannon Kenney

09:15 - 09:30 **Plenary 7.6 The LMP1-induced Phosphoproteome is Efficiently Targeted by Novel Small Molecule LMP1-TRAF2 Interaction Inhibitors in LCLs**, Arnd Kieser

09:30 - 09:45 **Plenary 7.7 Unveiling the Role of FAM50A in KSHV-Mediated RNA Splicing Alterations and Cellular Transformation**, Shou-Jiang Gao

09:45 - 10:00 **Plenary 7.8 Polymerase Theta is a Synthetic Lethal Target for Killing Epstein-Barr Virus Lymphomas**, Sumita Bhaduri-McIntosh

Coffee Break
10:00 - 10:30am Monday, 1st July
Grand Ballroom B & Ballroom Foyer

Keynote Address III: Exploring the Druggability of two Key KSHV Proteins Required for Viral Persistence and Inflammation
Thomas Schulz, Hannover Medical School, Germany
10:30 - 11:00am Monday, 1st July
Grand Ballroom A - Moderator: Mandy Muller

Parallel Session 8 Transformation/oncogenesis II
11:00am - 1:00pm Monday, 1st July
Grand Ballroom A
Moderators Meir Shamay, Kathy Shair

11:00 - 11:15 **Parallel 8.1 EBNA-LP Cooperates with YY1 in Promoting B Cell Transformation Through Changes in Chromatin Architecture**, Davide Maestri

11:15 - 11:30 **Parallel 8.2 Epstein-Barr Virus Protein EBNA-LP Reduces Innate Anti-Viral Sensing and Inhibits SP140L, a Novel Restriction Factor of Herpesvirus Infection**, Jana Cable

11:30 - 11:45 **Parallel 8.3 Shared and Distinct Interactions of Type 1 and Type 2 Epstein-Barr Nuclear Antigen 2 with the Human Genome**, Leah Kottyan

11:45 - 12:00 **Parallel 8.4 Application of Primary effusion lymphoma model mice for developing novel therapeutics**, Seiji Okada

12:00 - 12:15 **Parallel 8.5 The knockout of Epstein-Barr virus lytic gene, BNRF1 causes a fragile growth of both EBV-infected and EBV-transformed cells**, Yoshitaka Sato

12:15 - 12:30 **Parallel 8.6 KSHV Infection Promotes Mesenchymal-to-Endothelial Transition for Kaposi's Sarcomagenesis**, Yan Yuan

12:30 - 12:45 **Parallel 8.7 Incorporation of Epstein-Barr viral variation implicates significance of LMP1 in survival prediction and prognostic subgrouping in Burkitt lymphoma**, Jeffrey Bailey

12:45 - 13:00 **Parallel 8.8 Ectopic Expression of KSHV miR-K12-9 Can Induce Transformation of immortalized and primary Endothelial Cells**, Lauren Gay

Parallel Session 9 Virus/Host Interactions I
11:00am - 1:00pm Monday, 1st July
Georgian Room
Moderators Marta Gaglia, Chong Wang

11:00 - 11:15 **Parallel 9.1 Epstein-Barr-Virus-Driven Cardiolipin Synthesis Sustains Metabolic Remodeling During B-cell Lymphomagenesis**, Rui Guo

11:15 - 11:30 **Parallel 9.2 EBV Latent Membrane Protein 1 Signaling Alters Cysteine Metabolism to Support Antioxidant Defense and to Protect Infected Cells from Ferroptosis Induction**, Eric Burton

11:30 - 11:45 **Parallel 9.3 EBV Antigen Expression and the Spatial Immune Landscape of Tonsils from Patients with Infectious Mononucleosis**, Ciara Leahy

11:45 - 12:00 **Parallel 9.4 KSHV promotes oncogenic FOS to inhibit nuclease AEN and transactivate RGS2 for AKT phosphorylation**, Vladimir Majerciak

12:00 - 12:15 **Parallel 9.5 KSHV Perturbs Mitochondrial Morphodynamics to Dampen Innate Immune Response for Dissemination**, Ig Zhu

12:15 - 12:30 **Parallel 9.6 Transcriptional Changes Induced by the G Protein-Coupled Receptor of KSHV Reveal Regulation of Multiple Aspects of B Cell Biology**, Anna K. Grosskopf

12:30 - 12:45 **Parallel 9.7 PINLYP regulates KSHV reactivation through cPLA2-mediated phospholipid metabolism**, Xiaozhen Liang

12:45 - 13:00 **Parallel 9.8 Selective autophagy impedes KSHV entry after recruiting the membrane damage sensor galectin-8 to virus-containing endosomes**, Katarina Wendy Schmidt

Lunch Break - Maggiano's Little Italy
1:00 - 2:45pm Monday, 1st July
Maggiano's Little Italy

For Monday's lunch we have reserved the entire Maggiano's Little Italy restaurant which is right next to the Hilton Boston Back Bay.

KSHV 2025 Workshop Organization Lunch Meeting will be held at the same time ***for all those who responded to the survey by June 10th,*** please go to the MJ O'Connors Restaurant, there is a private room in the back reserved for this lunch meeting.

Parallel Session 10 Virus Host Interactions II
2:45 - 4:45pm Monday, 1st July
Grand Ballroom A
Moderators Neelam Sharma-Walia, Italo Tempera

14:45 - 15:00 **Parallel 10.1 An Epstein-Barr lytic reporter virus reveals extensive host shutoff via BGLF5-independent mechanisms**, Alejandro Casco

15:00 - 15:15 **Parallel 10.2 Orthogonal CRISPR tiling screens identify viral genes essential for the survival of KSHV-transformed B cells**, Mark Manzano

15:15 - 15:30 **Parallel 10.3 Latent Epstein-Barr Virus Infection Collaborates with Myc Over-expression in Normal Human B Cells to Induce Burkitt-like Lymphomas in Mice**, Jillian Bristol

15:30 - 15:45 **Parallel 10.4 Epstein-Barr Virus Tegument Protein BNRF1 Restrains DNA Repair by Targeting Poly(ADP-ribosylation) Status**, Chih-Ying Lee

15:45 - 16:00 **Parallel 10.5 Identification and Characterization of Kaposi Sarcoma Associated-Herpesvirus Glycoprotein-Specific Neutralizing Antibodies as a Tool to Elucidate Mechanisms of Viral Transmission**, Jonathan Calero-Landa

16:00 - 16:15 **Parallel 10.6 Genome-wide CRISPR/Cas9 screen identifies TIM1 and TIM4 as host factors for Kaposi's sarcoma-associated herpesvirus (KSHV) and the related rhesus monkey rhadinovirus (RRV)**, Alexander Hahn

16:15 - 16:30 **Parallel 10.7 Intrinsic p53 Activation Restricts GHV-Driven Germinal Center B Cell Expansion during Latency Establishment**, Shana Owens

16:30 - 16:45 **Parallel 10.8 ERBB Family Members Tightly Regulate KSHV Flip from Latency to Lytic Replication**, Annabel Olson

Parallel Session 11 Autoimmunity including Multiple Sclerosis
2:45 - 4:45pm Monday, 1st July
Georgian Room
Moderators Leah Kottyan, Sizun Jiang

14:45 - 15:00 **Parallel 11.1 Selected T lymphocytes Specific for Autologous Epstein-Barr Virus Infected Cell Lines Are Enriched in Multiple Sclerosis Cerebrospinal Fluid**, John Lindsey

15:00 - 15:15 **Parallel 11.2 Heightened Epstein-Barr Virus Immunity and Potential Cross-Reactivities in Multiple Sclerosis**, Graham Taylor

15:15 - 15:30 **Parallel 11.3 Spontaneous lymphoblastoid cell lines (SLCLs) from patients with active multiple sclerosis (MS) reveal differences in viral and host gene expression relative to healthy controls and conventional LCLs**, Paul Lieberman

15:30 - 15:45 **Parallel 11.4 Anoctamin-2 is Encephalitogenic and is a Target of EBNA1 Adaptive Immune Responses in Multiple Sclerosis**, Olivia Thomas

15:45 - 16:00 **Parallel 11.5 Human studies of Multiple Sclerosis based on human data and biological samples**, Alberto Ascherio

16:00 - 16:15 **Parallel 11.6 Epstein-Barr Virus (EBV) encoded transcription co-factors (TFs) in EBV-infected B cells are strongly associated with the genetic risk loci of Systemic Lupus Erythematosus (SLE), independently, in East Asians (EAS) and Europeans (EU)**, John Harley

16:15 - 16:30 **Parallel 11.7 Exploring the Cellular Origin of Systemic Chronic Epstein-Barr Virus Disease**, Kimitoshi Goto

16:30 - 16:45 **Parallel 11.8 EBNA2 Mechanisms in Autoimmune Diseases**, Matthew T. Weirauch

Coffee Break
4:45 - 5:00pm Monday, 1st July
Grand Ballroom B & Ballroom Foyer

Henle Lecture/Keynote Address IV: An Odyssey to Uncover the Link Between EBV, Malaria and Burkitt Lymphoma
Rosemary Rochford, University of Colorado, USA
5:00 - 5:30pm Monday, 1st July
Grand Ballroom A - Moderator: Benjamin Gewurz

EBV Association Annual Members' Business Meeting
5:30 - 6:30pm Monday, 1st July
Grand Ballroom A

All members of the EBV Association, and other interested in the society, should plan to attend this annual business meeting to hear about the Society's finances, future meetings and membership.

Dinner Break, On Own till 8:00pm

Poster Session 2
8:00- 10:00 pm Monday, 1st July
Statler Room

Presenters will be at their posters as follows: Visit the ODD number Posters from 8:00 – 9:00pm and the EVEN number Posters from 9:00 – 10:00pm. Food & Beverage and Bars will be setup in Grand Ballroom B and the Ballroom Foyer

TUESDAY, JULY 2, 2024

Continental Breakfast
7:15 - 8:00am Tuesday, 2nd July
Grand Ballroom B & Ballroom Foyer

Plenary Session 12 Virus/Host Interactions III
8:00 - 10:00am Tuesday, 2nd July
Grand Ballroom A
Moderators Rob White, Laurie Krug

08:00 - 08:15 **Plenary 12.1 Targeting Cellular Transcription Factors Essential for EBV Replication**, Sankar Swaminathan

08:15 - 08:30 **Plenary 12.2 Changes in SUMO-modified Proteins upon EBV Reactivation Identifies TRIM24 and TRIM33 as Antiviral Factors and a Novel Role for BZLF1 in Disabling them**, Lori Frappier

08:30 - 08:45 **Plenary 12.3 Infection of Myeloid cells with MHV68 Reveals Multiple Restriction Points that Limit Productive Lytic Replication.**, Gabrielle Vragel

08:45 - 09:00 **Plenary 12.4 Macrophages and B cell latency, a possible link between KSHV and malaria?** Julie Tram

09:00 - 09:15 **Plenary 12.5 The role of TOPBP1 in oriP-dependent EBV latent DNA replication**, Dong-Yan Jin

09:15 - 09:30 **Plenary 12.6 Retinoblastoma Protein Restriction of E2F Activity is Required for EBV Productive Replication in the Differentiated Epithelium**, Rona S. Scott

09:30 - 09:45 **Plenary 12.7 Unveiling the Role of KSHV-Infected Human Mesenchymal Stem Cells in Kaposi's Sarcoma Initiation**, Julian Naipauer

09:45 - 10:00 **Plenary 12.8 Influence of Human and Viral IL-6 on KSHV Infection in Human Tonsil Lymphocytes**, Wajd Zakir

Coffee Break
10:00 - 10:30am Tuesday, 2nd July
Grand Ballroom B & Ballroom Foyer

Keynote Address V Sir Anthony Epstein Memorial Lecture: EBV sequence variation, disease and vaccination strategies, Professor Paul Farrell, Imperial College London, UK
10:30 - 11:00am Tuesday, 2nd July
Grand Ballroom A **-** Moderator: Ann Moormann



Parallel Session 13 Noncoding RNA
11:00am - 12:00pm Tuesday, 2nd July
Grand Ballroom A
Moderators Nate Ungerleider, Jessica Tucker

11:00 - 11:15 **Parallel 13.1 The kaposin RNA transcript is the architect of a successful KSHV infection**, Mariel Kleer

11:15 - 11:30 **Parallel 13.2 Interferon Induced CircRNAs Escape Herpesvirus Host Shutoff and Suppress Lytic Infection**, Sarah Dremel

11:30 - 11:45 **Parallel 13.3 Profiling miRNA changes in EBV lytic infection identifies a function for BZLF1 in upregulating miRNAs from the DLK1-DIO3 locus**, Ashley Campbell

11:45 - 12:00 **Parallel 13.4 Inhibition of Type I Interferon Signaling is a Conserved Function of Gamma-herpesvirus-encoded MicroRNAs**, Rebecca Skalsky

Parallel Session 14 Innate and adaptive immunity II: RNA degradation
11:00am - 12:00pm Tuesday, 2nd July
Georgian Room
Moderators Jun Zhao, Christopher Whitehurst

11:00 - 11:15 **Parallel 14.1 KSHV exploits the TLR3/TRIF pathogen sensing pathway to activate caspases and block type I interferon induction**, Marta Gaglia

11:15 - 11:30 **Parallel 14.2 MHV68 infection alters tRNA splicing and elicits tRNA cleavage**, Jessica Tucker

11:30 - 11:45 **Parallel 14.3 RBM25 is a new Restriction Factor against KSHV**, Guillaume Fiches

11:45 - 12:00 **Parallel 14.4 Evaluation of candidate RNaseH molecules for resistance to viral replication and transcription activator (RTA) to test the role of R-loops during Kaposi's sarcoma-associated herpesvirus (KSHV) infection.**, Julia Fox

Parallel Session 15 Structure
12:00 - 1:00pm Tuesday, 2nd July
Grand Ballroom A
Moderators Xinghong Dai, Allison Didychuk

12:00 - 12:15 **Parallel 15.1 Glycoprotein K8.1 is O-glycosylated in KSHV and K8.1-chimeric RRV**, Gavin Golas

12:15 - 12:30 **Parallel 15.2 Structural basis for the ligand promiscuity and high signaling activity of KSHV GPCR**, Dokyun Kim

12:30 - 12:45 **Parallel 15.3 Structure and antigenicity of Kaposi's sarcoma-associated herpesvirus glycoprotein B**, Cong Sun

12:45 - 13:00 **Parallel 15.4 Structure-Function Studies of EBNA1, a Critical Therapeutic Target for Epstein-Barr Virus-Associated Diseases**, Troy Messick

Parallel Session 16 Vaccines I: Disease Associations
12:00 - 1:00pm Tuesday, 2nd July
Georgian Room
Moderators Jennifer Totonchy, Miao Xu

12:00 - 12:15 **Parallel 16.1 Predictors of Postviral Symptoms Following Epstein-Barr-Virus-Associated Infectious Mononucleosis in Young People – Data from the IMMUC Study**, Lorenz Mihatsch

12:15 - 12:30 **Parallel 16.2 A Cocktail Nanovaccine Targeting Key Entry Glycoproteins Elicits High Levels of Neutralizing Antibodies Against EBV Infection**, Ling Zhong

12:30 - 12:45 **Parallel 16.3 Human Herpesvirus 8 Infection is Associated with Prostate Cancer Among IFNL4-ΔG Carriers**, Frank Jenkins

12:45 - 13:00 **Parallel 16.4 Different mutational landscape among HHV8/EBV-negative and HHV8- and/or EBV-positive effusion-based lymphomas?** Margherita Vannucchi

Lunch Break - Empire Garden in Chinatown
1:00 - 3:00pm Tuesday, 2nd July
Empire Garden in Chinatown

Tuesday's Group Lunch: Empire Garden in Chinatown, a 9-minute walk from the Hilton Boston Park Plaza. Empire Garden Restaurant, 690 Washington St, Boston. Please ask at Registration if you need any assistance with transportation.



Parallel Session 17 Vaccines II: Therapeutics, Clinical Care
3:00 - 4:30pm Tuesday, 2nd July
Grand Ballroom A
Moderators Ramya Ramaswami, Javier Ogembo

15:00 - 15:15 **Parallel 17.1 Targeted Eradication of EBV-Positive Cancer Cells by CRISPR/dCas9-Mediated EBV Reactivation in Conjugation with Ganciclovir**, Renfeng Li

15:15 - 15:30 **Parallel 17.2 Pembrolizumab in HIV-associated Kaposi Sarcoma**, Kathryn Lurain

15:30 - 15:45 **Parallel 17.3 Synthetic BZLF1-targeted transcriptional activator for efficient lytic induction therapy against EBV-associated epithelial cancers**, Man Wu

15:45 - 16:00 **Parallel 17.4 The Effects of Novel Cereblon-binding Immunomodulators on Primary Effusion Lymphoma and Burkitt's Lymphoma**, Emma Treco

16:00 - 16:15 **Parallel 17.5 Targeting Vulnerability of EBV Infection for Vaccine Development**, Mu-Sheng Zeng

16:15 - 16:30 **Parallel 17.6 A Lymph Node Targeted Molecular Adjuvant and Engineered Subunit Antigen Vaccine Promotes Potent Cellular and Humoral Immunity to Epstein - Barr virus in HLA-Expressing Mice**, Vijayendra Dasari

Parallel Session 18 Virus Host Interactions IV
3:00 - 4:30pm Tuesday, 2nd July
Georgian Room
Moderators Rui Guo, Andrew McGuire

15:00 - 15:15 **Parallel 18.1 The N6-Methyladenosine (m6A) Reader Protein YTHDF2 Is a Negative Regulator of The KSHV Nuclease SOX**, Rakesh Sarkar

15:15 - 15:30 **Parallel 18.2 Modulation of Lymphotoxin Œ≤ Surface Expression by Kaposi's Sarcoma-Associated Herpesvirus K3 through Glycosylation Interference**, Soowon Kang

15:30 - 15:45 **Parallel 18.3 Exploring Human Interleukin 6 (hIL6-) and Viral Interleukin 6 (vIL-6) Transcript Regulation in the face of KSHV-mediated Global RNA Decay**, Yahaira Bermudez

15:45 - 16:00 **Parallel 18.4 CRISPR Genetic Analyses of Genome-wide Lymphoblastoid B-cell NF-κB Target Genes**, Bidisha Mitra

16:00 – 16:15 **Parallel 18.5 ORF48 is Required for Optimal Lytic Replication of Kaposi's Sarcoma-Associated Herpesvirus**, Beatriz Veronese

16:15 - 16:30 **Parallel 18.6 KSHV Hijacks SOX18 Pioneering Activity to Facilitate Latent DNA Replication**, Krista Tuohinto

4:45 - 5:00pm
Tuesday, 2nd July
Grand Ballroom B & Ballroom Foyer
Coffee & Soft Drinks will be available from 4:30 - 5:00 PM

Parallel Session 17 (continued) Vaccines II: Therapeutics, Clinical Care
4:45 - 6:00pm Tuesday, 2nd July
Grand Ballroom A
Moderators Zhen Lin, Sidney Ogolla

16:45 - 17:00 **Parallel 17.7 Towards Improving Models of EBV-Associated Diffuse Large B-cell Lymphoma to Investigate New Therapeutic Strategies**, Aisling Ross

17:00 - 17:15 **Parallel 17.8 LANA1 CR1 deletion as a candidate for a therapeutic KSHV antigen vaccine**, Li Wan

17:15 - 17:30 **Parallel 17.9 Split Dosing of Nanatinostat (Nstat) and Impact on Anti-Tumor Activity in EBV-Infected Solid Tumors**, Ayman Elguindy

17:30 - 17:45 **Parallel 17.10 Implementation of a point-of-care diagnostic technology for Kaposi's Sarcoma for Sub-Saharan Africa**, Jason Manning

17:45 - 18:00 **Parallel 17.11 EBV-FlowRNA in the Diagnosis of EBV-Related Lymphoproliferative Disease**, Claire Shannon-Lowe

Parallel Session 18 (continued) Virus Host Interactions IV
4:45 - 6:00pm Tuesday, 2nd July
Georgian Room
Moderators Jian Zhu, Matthew Weirauch

16:45 - 17:00 **Parallel 18.7 The Role of EBV BRRF1 Gene in Host Alternative Splicing Interference**, Trang Nguyen

17:00 - 17:15 **Parallel 18.8 The Cancer-Risk Variant of EBNA1 Improves Nasopharyngeal Carcinoma Risk Prediction in an EBNA1 IgA Assay**, Benjamin Warner

17:15 - 17:30 **Parallel 18.9 EBV Infection and Immune Response Dynamics in Human Tonsil Organoids**, Mahina Tabassum Mitul

17:30 - 17:45 **Parallel 18.10 The interaction of Kaposi's sarcoma-associated herpesvirus processivity factor ORF59 with the cellular paraspeckle component SFPQ is crucial for lytic replication**, Subhash Verma

17:45 - 18:00 **Parallel 18.11 Epstein-Barr Virus (EBV) Protein LMP1 Inhibits the Unfolded Protein Response (UPR) in Telomerase-immortalized Normal Oral Keratinocytes (NOKs)**, Deo Singh

Gala Dinner (for all those who registered extra, name badges include Gala on the back, please wear you name badge to the event)
7:00 - 10:00pm Tuesday, 2nd July
Avenue 34 at the Hilton Boston Park Plaza

WEDNESDAY, JULY 3, 2024

Continental Breakfast
7:15 - 8:00am Wednesday, 3rd July
Grand Ballroom B & Ballroom Foyer

Plenary Session 19 Viral entry/egress/assembly
8:00 - 10:00am Wednesday, 3rd July
Grand Ballroom A
Moderators Jennifer Corcoran**,** Michael McInatosh

08:00 - 08:15 **Plenary 19.1 Glycoprotein K8.1 is critical for liver and bone marrow tropism of Kaposi's sarcoma-associated herpesvirus (KSHV) in the non-human primate marmoset infection model**, Alexander Hahn

08:15 - 08:30 **Plenary 19.2 Recombinant mAbs Define Sites of Vulnerability on the KSHV gH/gL Complex**, Andrew McGuire

08:30 - 08:45 **Plenary 19.3 Identifying Entry Receptors for KSHV in B cells**, Beniah Brumbaugh

08:45 - 09:00 **Plenary 19.4 Visualization of Nuclear Egress in KSHV-Reactivated Cells**, Ariana Calderón-Zavala

09:00 - 09:15 **Plenary 19.5 Novel Epstein-Barr Virus gp42 Antibodies Reveal Sites of Vulnerability for Receptor Binding and Fusion to B cells**, Wei Bu

09:15 - 09:30 **Plenary 19.6 Dissecting the Mechanisms Underlying the Formation of Herpesvirus Assembly Compartments Mediated by Liquid-liquid Phase Separation**, Hongyu Deng

09:30 - 09:45 **Plenary 19.7 Characterizing the subcellular localization of Kaposi's sarcoma-associated herpesvirus essential packaging factor ORF68**, Sara Gelles-Watnick

09:45 - 10:00 **Plenary 19.8 Genome-wide CRISPR/Cas9 Library Screening Identifies EBV Entry Host Factors in B cells**, Hongbo Wang

Coffee Break
10:00 - 10:15am Wednesday, 3rd July
Grand Ballroom B & Ballroom Foyer

Plenary Session 20 Cancer risk variants, pathogenesis
10:15am - 12:30pm Wednesday, 3rd July
Grand Ballroom A
Moderators Alexander Price, Zhiqiang Qin

10:15 - 10:30 **Plenary 20.1 Genomic Analyses of Epstein-Barr Virus (EBV) Discover Risk Variants of EBV Associated With Post-transplant Lymphoproliferative Disorder**, Alan KS Chiang

10:30 - 10:45 **Plenary 20.2 Characterization of EBV DNA in Saliva of an Asymptomatic University Cohort**, Logan George

10:45 - 11:00 **Plenary 20.3 A Selective HDAC-PROTAC Activates a Host Switch Upstream of the EBV Latent-to-Lytic Switch ZEBRA**, Beth Rousseau

11:00 - 11:15 **Plenary 20.4 Repression of Productive Lytic Replication by KSHV LANA Correlates with Reduced Gammaherpesvirus-specific Adaptive Immunity**, Steven Murdock

11:15 - 11:30 **Parallel 20.5 WT1 Upregulation by Lytic Induction of Kaposi Sarcoma Herpesvirus**, Ayana Morales

11:30 - 11:45 **Plenary 20.6 Uncovering the EBV Genomic Landscape in Sub-Saharan Africa: Implications for Burkitt Lymphoma**, Elshafa Ahmed

11:45 - 12:00 **Plenary 20.7 Targeting latency switch for the treatment of EBV+ lymphoma**, Isabella Kong

12:00 - 12:15 **Plenary 20.8 Cloning and Analysis of an EBV Strain from an LCL Established with a Kenyan Breast Milk-Derived Virus**, Rob White

12:15 - 12:30 **Plenary 20.9 Characterization of EBV infection in tonsils of children residing in malaria holoendemic region of western Kenya**, Emmily Koech

12:30 - 12:45 **Closing Statements**
Moderators Benjamin Gewurz, Kenneth Kaye

POSTER SESSION 1 PRESENTATIONS

P1.1 Epstein-Barr virus- and genotype- dependent transcriptional regulation at multiple sclerosis risk loci, Marissa Granitto

P1.3 The Oral Microbiome by HIV infection and KSHV shedding status in a rural Ugandan population, Katherine Sabourin

P1.5 Distinct Genomic Features of Transeurasian Strains of Epstein-Barr Virus, Hiroshi Kitamura

P1.6 Risk Factors for and Patterns of Oral Shedding of Kaposi's Sarcoma-Associated Herpesvirus – a Systematic Review, Katherine Sabourin

P1.7 EBV Genomic Landscape in Multiple EBV+ Malignancies Reveals Distinctive Geographic-Constrained Characteristics., Rosario Distefano

P1.8 Evaluation of triage performance of the Epstein–Barr virus C promoter methylation assay in serology positive population: validation in two mass nasopharyngeal carcinoma screening cohorts, Sumei Cao

P1.9 Haplotype Analysis of EBV Genomes in Nasopharyngeal Carcinoma and Prediction of High Risk EBV Lineage Using a Panel of Nine SNPs, Alan Kwok Shing Chiang

P1.10 The Interplay Between EBV Subtypes and Host Genetic Factors on NPC Susceptibility, Miao Xu

P1.11 EBV Latency Programs Modulate Sensitivity to Necroptosis in a BCL6 Dependent Manner, Nina Beri

P1.12 Heat Shock Factor 2 sustains the lytic cycle of both oncogenic human gamma-herpesviruses, Silvia Gramolelli

P1.13 XPB, the Translocase and Helicase of TFIIH, Regulates KSHV DNA Replication and Late Gene Expression, Harriet Song

P1.14 Re-analysis of plasma EBV bisulfite sequencing shows novel differentially methylated CpG sites in EBV(+) cancers, Wendell Alejo

P1.15 A GC-rich DNA cis Element in the KSHV Genome Drives the Elevated Expression of the KSHV Lytic Gene ORF75 in Kaposi's Sarcoma Lesions, Ashwin Nair

P1.16 HuSH EBV: An unexpected inhibitory complex of EBV in Burkitt Lymphoma, Madilyn Ellis

P1.18 Novel Multiplex RT-qPCR for Detection of EBV RNA in EBV Associated Gastric Cancer Tissue, Aisha Babi

P1.19 Advancing Primary Effusion Lymphoma Treatment: The Pivotal Role of a New Epigenetic Therapy Combining KDM4A and HDAC Inhibition, Pei-Ching Chang

P1.20 EBV Antigen Expression in the Tonsils of Patients with Infectious Mononucleosis, Aoife Hennessy

P1.21 Local CD4 T Cell Response in Pediatric Patients With EBV Infection, Paola Andrea Chabay

P1.22 Modulation of Inflammasomes During Latent Kaposi's Sarcoma Herpesvirus Infection, Christina Yap

P1.23 Proteome-wide analysis reveals a core Epstein-Barr Virus antibody signature for classic Hodgkin Lymphoma., Yomani Sarathkumara

P1.25 Increased HHV-8 Neutralising Response during Remission from Kaposi's Sarcoma, Frank Neipel

P1.26 Generating a Mouse Model Able to Recapitulate Kaposi Sarcoma Herpesvirus-Associated Malignancies., Vicenta Trujillo

P1.27 Estimating the Replication and Segregation Efficacy of KSHV Episomes, Madeleine Gastonguay

P1.28 Single cell transcriptome of EBV+ lymphomas and lymphadenopathies from people living with HIV, Maria Montserrat Aguilar Hernandez

P1.29 Polycomb Group Proteins Modulate Viral Transcription and Prevent Episome Clearance of KSHV, Adam Grundhoff

P1.30 Chemotherapeutic agents induce Epstein-Barr virus lytic reactivation in epithelial cells through caspase-dependent apoptosis and downregulation of IFIT protein expression, Chon Phin Ong

P1.31 NSUN1/2-mediated RNA m5C modification controls KSHV viral infection via regulating RNA stability of host restriction factors, Zhenyu Wu

P1.32 Dynamic Landscapes: The Role of m6A Machinery in Reshaping the Transcriptome during Viral Infection, Kyla Gomard-Henshaw

P1.33 Vascular Endothelial Growth Factor Receptor (VEGFR3/FLT4) Regulates the KSHV Replication Cycle, Ameera Mungale

P1.34 Bruton's Tyrosine Kinase Activates the NLRP3 Inflammasome to Reactivate Epstein-Barr Virus from Latency, Travis Zeigler

P1.35 The Histone H3K79 Methyltransferase DOT1L Restricts EBV Lytic Reactivation, Jinjie Yan

P1.36 Human Herpes Virus-8 Shedding Heterogeneity is Due to Varying Rates of Reactivation from Latency and Immune Containment, Warren Phipps

P1.37 Autophagy is Maintained at a Constant Level at Different Levels of Lytic Reactivation and at the Production of Virions of Epstein-Barr Virus, Jia Xie

P1.38 Histone Demethylase KDM1A restricts EBV lytic reactivation, Yifei Liao

P1.39 Hypoxia induces a 5-methyl-THF trap that remodels host and viral epigenome during EBV de novo infection, Larissa Havey

P1.40 PD-L1 Exosome Has a Potential as a Prognostic Factor in Nasopharyngeal Carcinoma, Eiji Kobayashi

P1.41 Dependence of EBV-positive Diffuse Large B Cell Lymphomas on ZFP91 Unveils Susceptibility to a Novel CELMoD, Huanzhou Xu

P1.42 Morphological Analysis of EBV-Positive Nasopharyngeal Carcinoma Cells, Shigetaka Komura

P1.43 Characterization of single nucleotide and structural variations in the Epstein–Barr viral genome, Htet Thiri Khine

P1.44 Defining the Role of Epstein-Barr Virus (EBV) in Diffuse Large B-Cell Lymphoma (DLBCL) Pathogenesis, Quincy Rosemarie

P1.45 Insights into the Curious Absence of EBV-driven Lymphoma in X-linked Lymphoproliferative Disease 2 (XLP2) Patients, Yizhe Sun

P1.46 Epstein-Barr virus Selective Whole Genome Amplification Combined with Multiplex PCR Allows For Long-read Sequencing and Accurate Whole Genome Assembly from Burkitt lymphoma, Enrique Puig III

P1.47 Epstein-Barr Virus Types in Childhood Cancers: Assessment in a Malawian Cohort, Gabriela Samayoa Reyes

P1.48 Acetyl-CoA Carboxylase Alpha elevated by LMP1 Promotes Malignant Behavior of Nasopharyngeal Carcinoma by modulating lipid metabolism, Zhe Zhang

P1.50 Sulfonated Cyclodextrins are Virucidal against KSHV and EBV and Mitigate KSHV Infection in Vivo., Alma Delia Valencia-Camargo

P1.51 The VSV-based EBV GB Vaccine Elicits a Robust Immune Response Against EBV Infection, Guo-Long Bu

P1.52 Saliva Kaposi Sarcoma Herpesvirus Levels as a Diagnostic Marker of Visceral Kaposi Sarcoma, Matthew Witterholt

P1.53 Development of KSHV vaccine platforms and chimeric MHV68-K-K8.1 for evaluating the in vivo immunogenicity and efficacy of KSHV vaccine candidates, Wan-Shan Yang

P1.54 Dendritic Cell-Based Vaccines (KSD-101) Against EBV-Associated Hematologic Neoplasms: Results from an Ongoing Phase I Clinical Study, Chunrui Li

P1.55 A Chimeric gH/gL Nanoparticle Vaccine Elicits Robust Protective Humoral Immunity Against EBV and KSHV, Chu Xie

P1.56 Development of Human Single-Chain Variable Fragment (scFv) Phage Library Targeting KSHV Proteins, Ziyi Liu

P1.57 Title: A Case Report of Ebstein-Barr Virus (EBV) Infection: Clinical Presentation and Management, Uwesu Muki

P1.58 A Complex Case Report of Kaposi's Sarcoma in a Patient from Tanzania: Clinical Challenges and Management Strategies, Uwesu Muki

P1.59 Pomalidomide and Liposomal Doxorubicin for Kaposi Sarcoma with or without other KSHV-associated Diseases, Ramya Ramaswami

P1.60 Virus-Like Particle AP205 Based Vaccine Candidates Elicit Strong Protective Responses against Epstein-Barr Virus Infection, Yanan Peng

P1.61 Exploration of Lysine Targeting Covalent Inhibitors of Epstein-Barr Virus Nuclear Antigen 1: Towards Anti-EBV Therapeutics, Elizabeth Day

P1.62 The Impact of EBV Strains and Genes on Epithelial Cell Infection Mediated by EBV-Transformed Human B Cells, Ming-Han Tsai

P1.63 Investigating the Oligomeric State of KSHV ORF68, an Essential Viral Genome Packaging Factor, Olaide Adeyemi

P1.64 Protective Anti-gB Neutralizing Antibodies Targeting Two Vulnerable Sites for EBV-Cell Membrane Fusion, Miao Xu

P1.65 Infection of Human Differentiated Cardiomyocytes by an Oncogenic Virus, Jiaojiao Fan

P1.66 EBV infection mediated BDNF expression is associated with bladderinflammation in interstitial cystitis/bladder pain syndrome withHunner's lesion, Chih-Wen Peng

P1.67 Investigating Type 1 and Type 2 Epstein-Barr Virus Persistence in Human Immune Compartments Using Humanized Mice, Saskia Müller[1]

P1.68 EBV's BPLF1 Deubiquitinates mTOR and Dysregulates its Downstream Targets, Rachel Mund

P1.69 Neuropilin-1 as a host dependency factor of Kaposi Sarcoma Herpesvirus/Human Herpesvirus-8, Anna Serquina

P1.70 Cerebral Brain Organoid Co-Culture: A Novel Technique to Study the Temporal and Spatial Dynamics of EBV+ B-cell Invasion, Danielle Burner

P1.71 Exploring the Role of Interferon-alpha in Endemic Burkitt Lymphoma Pathogenesis and Rituximab Efficacy, Ann Kinyua

P1.72 Syncytin-1 Sequesters Viral LF2 to Enhance the Epstein-Barr Virus Lytic Phase., Ibukun Akinyemi

P1.73 Merkel cell polyomavirus ALTO activates NF-κB signaling like EBV LMP1 but suppresses tumorigenesis and is silenced in Merkel cell carcinoma, Nick Salisbury

P1.74 Understanding the Role of Interindividual Variability in the Response to EBV Infection of Primary B Cells, Francesco Baccianti

P1.75 Heterogeneous Outcomes of Myeloid Cell Infection by MHV68 Implicate Interferon Signaling as a Potential Regulator, Rachael E. Kostelecky

P1.76 Dynamic Repertoire of MHV68-Infected B Cells and Persistent Expression of the ORF46 Viral Uracil DNA Glycosylase in Latency, Kevin McBride

P1.77 An Epstein-Barr Virus Protein Interaction Map Reveals NLRP3 Inflammasome Evasion via MAVS UFMylation, Stephanie Pei Tung Yiu

P1.78 Structural Basis of KicGAS Self-oligomerization and its Inhibition of cGAS, Fanxiu Zhu

P1.79 Dihydrotestosterone boosts the MICA-mediated cytotoxicity via EBV lytic reactivation, Hyojeung Kang

P1.80 Developing a Primate-Like Small Animal Model to Investigate Epstein-Barr virus (EBV)-Infection and Associated Diseases, Hirotomo Dochi

P1.81 Spatial Transcriptomics of Patients with Kaposi Sarcoma Identifies Mechanisms of Immune Evasion, Joseph Ziegelbauer

P1.82 Systematic Examination of EBV Transcriptional Regulator Interactions with the Host Genome, Phillip J. Dexheimer

P1.83 Genotype-Dependent Binding of Viral Protein Zta to Autoimmune-Associated Genetic Variants, Carmy Forney

P1.84 Elimination of EBV-infected B-cells with a Novel Combination Regimen, Nanatinostat and Valganciclovir, Provides Potential Therapeutic Benefit in a Humanized Mouse Model of Multiple Sclerosis, Ayman Elguindy

P1.85 Interrogating Patient Susceptibility and Resistance to Epstein-Barr Virus Infection in the Nasopharynx using Organotypic Cultures, Joshua Walston

POSTER SESSION 2 PRESENTATIONS

P2.1 Isolation, Purification, and Characterization of KSHV and KSHV Viral Particles in Infection Models, Akash Mody

P2.2 Impact of MHV-68's Hepatotropism on a Subsequent Liver Infection by Malaria Parasites, Andreia Mósca

P2.3 Spectrum of KSHV/HHV8 and EBV Related Lymphoproprolipherative disorders: Challenges in the Daily Routine., Lorenzo Leoncini

P2.4 Burden, Pattern, Associated Factors and Impact on Quality of Life of Dermatological Disorders among the Elderly in Ilala Municipality, Dar es Salaam., Uwesu Muki

P2.5 Clinical features and prognostic factors of adult systemic chronic active Epstein-Barr virus disease: A retrospective analysis using Japanese registry data, Hiroshi Yasui

P2.7 Sex differences in anti-EBV antibody responses, Zhiwei Liu

P2.8 Shedding of Kaposi Sarcoma-associated Herpesvirus (KSHV) and Epstein-Barr Virus (EBV) DNA in Oral Fluids of Rural Community-Dwelling Adults and Adolescents in Uganda, Kyle Moore

P2.9 Genome sequence analysis clarifies Epstein-Barr virus genome variations enhances clinicopathological features of nasopharyngeal cancer in non-endemic area, Japan, Satoru Kondo

P2.10 What's Old is New Again: Arginine Metabolism Supports EBV Latency in Burkitt Cells Due to Obligatory Roles in Pyrimidine Biosynthesis, Shaowen White

P2.11 Epstein-Barr Virus is Required for Continued Proliferation of Newly Derived Endemic Burkitt Lymphoma Cell Lines, Alexandria Bartlett

P2.12 Characterizing Methylation of EBV DNA in Tumors and Plasma Using a Novel Quantitative Method, Logan George

P2.13 Epstein-Barr Virus (EBV) DNA methylation patterns in liquid biopsies inform viral reactivation and disease course in lymphoproliferative disease, Christoph Weigel

P2.14 LANA cross-links to KSHV terminal repeat (TR) regulate episome maintenance and epigenetic programming, Paul Lieberman

P2.15 Modular Assembly of an Infectious Clone of EBV Akata using Synthetic Genomics Methods in Yeast, Sydney Ghoreishi

P2.16 B-cell Receptor Isotype and the Epstein-Barr Virus (EBV) LMP2A Oncogene Regulate Distinct Genes in EBV Transformed Cells, Mariah Riel

P2.17 Comparative Functional Screens Highlight a Role for CDK9 in KSHV Late Gene Transcription, Chad Stein

P2.18 Promoter Binding by the KSHV Late Viral Transcriptional Activator Requires an Extended DNA Binding Domain and Cytoplasmic Assembly of the Transcription Preinitiation Complex, Lidia Llacsahuanga-Allcca

P2.19 Epigenetic Regulation of EBV Viral Kinase BGLF4in EBV+ CNS Lymphoproliferative Disease as a Potential Biomarker for Antiviral Susceptibility, Haley Klimaszewski

P2.20 EBV Lytic Reactivation Attenuates Interferon Signaling through m6A Modification of the Host Epitranscriptomes, Dipayan Bose

P2.21 Genome-Wide Analysis of Epstein-Barr Virus (EBV) in Lymphoma Patients from Ethiopia, Elshafa H Ahmed

P2.22 ISG15 Emerges as a New Pro-Viral Host Factor in EBV-Mediated B-Cell Transformation., Nicolas Reinoso-Vizcaino

P2.24 High-Throughput In-Silico Exploration of T-Cell Responses to Kaposi Sarcoma Herpesvirus, Shashidhar Ravishankar

P2.25 Persistence of T-cell dysfunction is associated with lack of treatment response in Kaposi sarcoma, Andrea M.H. Towlerton

P2.26 High Levels of Antibodies Target the C-Terminus of EBNA1 in Acute Infectious Mononucleosis, Krishna kumar Ganta

P2.27 EBV Latent Infection Activates the Keap1-NRF2 Antioxidant Defense, Shunbin Ning

P2.28 The Chromatin Loop Release Factor WAPL Regulates EBV Latency Status by Restricting LMP Production, Laura Murray-Nerger

P2.29 Characterization of the Latency-Associated Nuclear Antigen SUMO-Interacting Motif in Kaposi's Sarcoma-Associated Herpesvirus (KSHV), Catarina Costa

P2.30 Human Genome-wide CRISPR/Cas9 Screen Reveals STEEP1 as a Key Host Factor for LMP1 Trafficking and Signaling, Shunji Li

P2.31 Utilizing Single-Cell RNA Sequencing to Uncover Host Factors Involved in Preventing Successful EBV Lytic Reactivation, Lauren Haynes

P2.32 Epstein-Barr Virus-Induced Nodules on Viral Replication Compartments Contain RNA Processing Proteins and a Viral Long Noncoding RNA, Richard Park

P2.33 A Deep Mutational Scanning Approach to Identify Key Residues of Viral Transcriptional Activators Necessary for Late Gene Transcription, Nicholas R. Doak

P2.34 Transcriptome Reprogramming of Epstein-Barr Virus Infected Epithelial and B Cells Reveals Distinct Host-virus Interaction Profiles, Nian Ma

P2.35 Unraveling the Role of G-Quadruplexes in Kaposi's Sarcoma-Associated Herpesvirus DNA Replication., Subhash Verma

P2.36 KSHV lytic replication is dependent on eIF3D, Craig McCormick

P2.37 Visualization of Nuclear Egress in KSHV-Reactivated Cells, Ariana Ariana Calderón-Zavala

P2.38 Identification of Synthetic Lethality in Epstein-Barr Virus Associated Gastric Cancer, Yin Wang

P2.39 Genome-wide CRISPRi Screen to Identify Host Long Non-coding RNA Dependencies of KSHV Infection, Sarah McMahon

P2.40 Characterizing the Antiviral activity of SLFNs during MHV68 infection., Sheila Gonzalez

P2.41 Epstein-Barr virus in HIV-associated conjunctival squamous cell carcinoma, Hirotomo Dochi

P2.42 Molecular Studies in Patients from Argentina with EBV+ Diffuse Large B-cell Lymphoma, not Otherwise Specified (EBV+ DLBCL, NOS) and DLBCL with Viral Traces., Paola Chabay

P2.43 Epstein-Barr virus uses different BNRF1 splicing variants depending on the situation, Shiori Endo

P2.44 KSHV Infection Leads to Osteosarcoma in Xinjiang Uyghur Population, Yan Yuan

P2.45 PD-L1 Expression by Myeloid Derived Suppressor Cells in Pediatric Hodgkin Lymphoma, Paola Chabay

P2.46 Assessment of Potential Transforming Properties of KSHV gL as Revealed Through Rhesus Macaque Rhadinovirus Chimeras Expressing KSHV Envelope Glycoproteins, Ryan Estep

P2.47 Identifying cellular gene dependencies in EBV-positive Burkitt Lymphoma, Isabella Castellano-Moen

P2.48 Peritumoral SPARC expression is induced by exosomes from tumor cells and is associated with poor prognosis in the patients with Epstein-Barr virus-associated nasopharyngeal carcinoma., Tomokazu Yoshizaki

P2.50 Kaposi Sarcoma (KS) Patient-derived Xenografts from Skin Tumors Exhibit High Expression Levels of Viral Genes and Hallmark KS Genes, Xiaofan Li

P2.51 Comparison of antibody functions between people living with HIV and KSHV in the United States and Zambia, Marina Tuyishime

P2.52 Exploring DARPins to Detect MHC-I Restricted Antigen Presentation, Sandra Schmid

P2.53 Geographic EBV variants confound disease-specific variant interpretation and predict variable immune therapy responses, Edward Briercheck

P2.54 Multivalent MVA-Vectored Vaccine Elicits EBV Neutralizing Antibodies in Rhesus Macaques that Reduce EBV Infection in Humanized Mice, Brenda Alvarado

P2.55 Establish an Immunosuppressive Regimen in Common Marmosets (Callithrix jacchus) for use in Viral Challenge Experiments, Esther Rodriguez

P2.56 Targeting HERV-K by ART drugs for the treatment of Primary Effusion Lymphoma, Anuj Ahuja

P2.57 Caspase-mediated AURKA cleavage at Asp132 is essential for viral and paclitaxel-induced cell apoptosis, Xiaoting Chen

P2.58 Kaposi's sarcoma-associated herpesvirus (KSHV)-associated primary effusion lymphoma (PEL) tumor formation in NOD/SCID mice is inhibited by treatment with the anti-inflammatory Lipoxin A4, Neelam Sharma-Walia

P2.60 Identification of new natural products for preventing primary infection of an oncogenic herpesvirus, Zhiqiang Qin

P2.61 Neuropilin-1 is a universal host factor mediating herpesvirus infection., Zheng-Zhou Lu

P2.63 Kaposi's sarcoma-associated herpesvirus (KSHV) gB dictates a low-pH endocytotic entry pathway as revealed by a dual-fluorescent virus system and a rhesus monkey rhadinovirus (RRV) expressing KSHV gB, Alexander Hahn

P2.64 The Role of Epstein Barr Virus (EBV) in Pathogenesis of EBV-associated T/NK Lymphoproliferative Diseases, Zhaoqin Zhang

P2.65 Exploring the Role of Epstein-Barr Virus in MS Pathogenesis Through the Lens of Atypical B Cells, Gillian Horn

P2.66 Evidence for Variant EBV-Positive B-Cell Subtypes Associated with MS, Leena Yoon

P2.68 PIAS1 Regulates Episome Maintenance to Control the Life Cycles of EBV, KSHV and HPV, Febri Sugiokto

P2.71 Mechanism of APOBEC3B Relocalization by Epstein-Barr virus BORF2, Farren Clark

P2.72 Epstein–Barr virus positivity as a defining pathogenetic feature of Burkitt lymphoma subtypes., Lorenzo Leoncini

P2.73 The DNA Repair Machineries for Double-strand DNA Breaks Circularize KSHV and HSV, Shijun Li

P2.74 Elucidating the Pathogenic Mechanisms of Angiopathy in Systemic Chronic Active Epstein-Barr Virus Disease through Induced Pluripotent Stem Cell-Derived Endothelial Cells, Miwako Nishio

P2.75 Profiling of Epstein-Barr virus glycoproteins-host interactome by chemical proteomics, Lanyi Zhong

P2.77 The Presence of LMP1 in the Tumour Cells of Caucasian Patients with ENKTL is Associated with an M1-Macrophage Rich Tumour Microenvironment and Predicts Longer Overall Survival, Ciara Leahy

P2.78 Host and viral gene regulation by circular RNAs in EBV-positive B cells, Takanobu Tagawa

P2.79 EBV Infection Induces RSAD2 and CMPK2 to Promote Viral Latency and Modulate Interferon Response, Urvi Zankharia

P2.80 An Oxygen-Independent Role for eIF5B in Translation Initiation during KSHV Replication and Oncogenesis, Christian McDonald

P2.81 Methylation of KSHV vCyclin by PRMT5 Contributes to Cell Cycle Progression and Cell Proliferation, Danping Niu

P2.82 Prediction of Caspase Cleavage Sites in KSHV Proteins: Validation of K5 as another KSHV Caspase Target, David Davis

P2.85 EBNA2 Activates DNA Damage Response for Immune Evasion, Eleni Anastasiadou

ePoster 1 (please view through the online program) **Degradation of TRIM32 is induced by RTA for Kaposi's Sarcoma-Associated Herpesvirus lytic replication,** Yulin Zhang

NOTES

NOTES

NOTES

NOTES

PROGRAM AT A GLANCE

	Saturday, June 29	
17:00	Welcome & Introductions - Plenary Session 1 Coinfections - Terrace Room	
19:15	Welcome Reception - Statler Room	
	Grand Ballroom A	**Georgian Room**
	Sunday, June 30	
7:15	Continental Breakfast & Registration - Grand Ballroom B & Foyer	
8:00	Plenary Session 2 Tumor Microenvironment	
10:00	Coffee Break	
10:30	Keynote Address I - Ethel Cesarman	
11:00	Parallel Session 3 Epigenetics, Gene Expression & Reactivation II	Parallel Session 4 Innate & Adaptive Immunity !: Viral Evasion
13:00	Lunch Break Panera Bread	
14:45	Parallel Session 5 Epigenetics, Gene Expression & Reactivation II	Parall Session 6 Lytic Cycle/Viral Replication/Reactivagion I
16:45	Coffee Break	
17:00	Keynote Address II Elliott Kieff Memorial Lecture - Nancy Raab-Traub	
17:30	In Memoriam	
17:45	Poster Session 1 - Statler Room	
	Monday, July 1	
7:15	Continental Breakfast - Grand Ballroom B & Foyer	
8:00	Plenary Session 7 Transformation/oncogenesis I	
10:00	Coffee Break	
10:30	Keynote Address III - Thomas Schulz	
11:00	Parallel Session 8 Transformation/oncogenesis II	Parallel Session 9 Virus/Host Interactions I
13:00	Lunch Break Maggiano's Little Italy & KSHV 2025 Organizing Lunch MJ O'Connor's for those who signed up	
14:45	Parallel Session 10 Virus/Host Interactions II	Parall Session 11 Autoimmunity including Multiple Sclerosis
16:45	Coffee Break	
17:00	Henle Lecture/Keynote Address IV - Rosemary Rochford	
17:30	EBV Association Meeting	
	Dinner Break On-Own	
20:00	Poster Session 2 - Statler Room	
	Tuesday, July 2	
7:15	Continental Breakfast - Grand Ballroom B & Foyer	
8:00	Plenary Session 12 Virus/Host Interactions III	
10:00	Coffee Break	
10:30	Keynote Address V Sir Anthony Epstein Memorial Lecture - Paul Farrell	
11:00	Parallel Session 13 Noncoding RNA	Parallel Session 14 Innate and adaptive immunity II: RNA degradation
12:00	Parallel Session 15 Structure	Parallel Session 16 Vaccines I: Disease association
13:00	Lunch Break Empire Garden in Chinatown	
15:00	Parallel Session 17 Vaccines II: Therapeutics, clinical care	Parall Session 18 Virus Host Interactions IV
16:30	Coffee Break	
16:45	Parallel Session 17 (continued) Vaccines II:	Parall Session 18 (continued) Virus Host
19:00	Gala Dinner (additional ticket required) - Avenue 34 at the Hilton	
	Wednesday, July 3	
7:15	Continental Breakfast - Grand Ballroom B & Foyer	
8:00	Plenary Session 19 Viral entry/egress/assembly	
10:00	Coffee Break	
10:15	Plenary Session 20 Cancer risk variants, pathogenesis	
12:30	Closing Statements	
12:45	Adjourn